This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness data were derived from a single study.
Link between effectiveness and cost data
The costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.
Study sample
Two hundred patients were recruited over 2 years, 100 in each of the TAH and LAVH groups. It was stated that 120 patients per arm would allow an 80% chance of detecting a 15% difference in the complication rates at a 5% level. In addition, 25 patients per arm were required to detect a difference of 2 days in the hospital stay.
Seven women did not attend for the operation, and the case records were not available for a further 3 patients. The resultant sample size was 190 patients. There were 95 patients in the TAH group and 95 in the LAVH group. The baseline characteristics and indications for surgery were reported, thus enabling the study sample to be compared with the study population.
Study design
The study was a prospective randomised controlled trial carried out at three centres. Patients were followed-up for one year. Eight of the women randomised to the LAVH group did not undergo LAVH. This was because of "peri-operative difficulty" or complications (3 patients), patient preference (2 patients), and a very difficult LAVH was anticipated at endoscopy (3 patients).
The response rate for the patient questionnaire was 81 for TAH and 85 for LAVH. The response rates for the EuroQol instrument were: 76 for TAH and 74 for LAVH, 1 month after surgery; 61 for TAH and 62 for LAVH, 6 months after surgery; and 47 for TAH and 43 for LAVH, 1 year after surgery.
Analysis of effectiveness
The analysis of the clinical study was stated to have been on an intention to treat basis. However, there were losses to follow-up with the questionnaire and EuroQol instrument, which were not accounted for. The primary health outcomes were the complication rates, self-reported problems and milestones, and the quality of life (EuroQol 5D visual analogue scale). There were no significant differences between the groups in terms of their demographic characteristics, or the presence of pelvic pathology at the start of the trial.
Effectiveness results
The duration of the operation was 45 minutes for TAH and 80 minutes for LAVH.
The overall complication rate was 14% for TAH and 8% for LAVH.
Major complications occurred in 6 women undergoing LAVH and one woman undergoing TAH.
Two women (one in each group) experienced ureteric damage.
The other major complications were haemorrhage requiring transfusion (n=2), pulmonary embolism (n=1), severe infection requiring intensive care unit (ITU) admission (n=1), and bladder damage (n=1).
With the exception of pyrexia, the TAH group experienced more minor complications.
Fourteen patients, 8 in the LAVH group and 6 in the TAH group, were readmitted. Of these, 5 required further treatment due to a vault haematoma (2 TAH; 1 LAVH) and for reimplantation of the ureter (1 TAH; 1 LAVH).
There were no significant differences in the self-reported post-operative problems, except for the category of "other problems". This included tiredness and constipation, which were higher for the women undergoing LAVH, (p=0.02).
There was reported to have been no difference in the time taken to achieve the post-operative milestones, but the data were not shown.
The mean changes in the EuroQol score (+/-standard deviation) were: at 1 month, TAH 6.8 (+/-19.2) and LAVH 7 (+/-24.1); at 6 months, TAH 14.9 (+/-16.7) and LAVH 11.3 (+/-23.9); and at 1 year, TAH 15.9 (+/-21) and LAVH 12.6 (+/-2.5).
There was stated to have been no significant differences.
Overall, LAVH produced more complications and a statistically-significant number of more problems falling into the
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Clinical conclusions
LAVH was associated with a reduction in the length of hospital stay. Both the recovery following operation and patient satisfaction were not affected by the route chosen.
Measure of benefits used in the economic analysis
No summary measure was used. The study should therefore be considered as a cost-consequences analysis.
Direct costs
The direct costs were not discounted since the timeframe of the study was less than one year. The direct costs included the costs of pre-operative stay, blood tests, operation details, pain relief, post-operative stay, complications, additional surgery, and readmissions. The quantities were only given for length of stay, rates of admission to ITU, the number of women requiring additional surgery, the number of readmissions, and the number of blood transfusions. The unit costs were not given. The quantity/cost boundary adopted was that of the hospital. The quantities and costs were estimated from actual data. The costs and quantities were obtained from National Health Service sources. The price year was 1997 to 1998.
Statistical analysis of costs
Appropriate non-parametric tests were performed on the cost estimates. The authors reported the mean total costs.
Indirect Costs
The indirect costs were not included.
Currency

UK pounds sterling ().
Sensitivity analysis
Sensitivity analyses were conducted on the cost estimates, doubling or halving the cost per inpatient day or per minute in the theatre.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total costs amounted to 1,832 for TAH and 2,479 for LAVH. The sensitivity analysis revealed that LAVH was associated with higher mean costs than TAH assuming the following: cost per minute in theatre halved, cost per inpatient day doubled and no disposable costs. The mean difference in total cost () between TAH and LAVH was -647, (95% confidence interval: -1,181, -113)
The power calculation recommended 120 patients per arm, which is considerably more than were actually recruited and many more than were followed-up. The calculation was based on detecting a difference in the complication rates, which did not seem to have been analysed statistically. In addition, it did not account for the only longer-term measure, the EuroQol instrument, which showed LAVH was better than TAH on average. The lack of statistical significance could therefore have been due to a low sample size coupled with a high drop-out rate.
Validity of estimate of measure of benefit
Not applicable given that a cost-consequences analysis was conducted.
Validity of estimate of costs
A good feature of the cost analysis was that all relevant direct cost categories appear to have been included. The generalisability to other settings was hampered by the fact that a complete breakdown of resource quantities and unit costs was not given. Also, the sensitivity analysis was conducted for the cost input or cost output only, with the ranges chosen arbitrarily (halving or doubling).
